fbpx JLABS Company News | JLABS

News


Other news

Want to know more about the JLABS Portfolio?

By JLABS

Read full story

Seoul Innovation QuickFire Challenge: Robotics & Digital Surgery

JLABS | Lung Cancer QuickFire Challenge
Seoul Innovation QuickFire Challenge: Robotics & Digital Surgery QFC
Challenge ended

KRW 150M (~$134k) + Entrance to Seoul Bio Hub + Mentorship

Digital Health
Surgery

Winners

 

medipixel%20logo_1-1.png

Seoul-based Medipixel is a start-up that applies artificial intelligence (AI) into robotic surgery, starting with percutaneous coronary intervention (PCI). Their AI-based robotic PCI solution helps surgeons choose the most suitable devices and guides devices precisely without human intervention

 

Bilab%20Logo.png

Seoul-based BiLab is a start-up that develops and produces non-invasive continuous monitoring medical devices of cardiopulmonary functions using electrical impedance tomography (EIT) for hypoventilation, hemodynamics, and sleep apnea diagnostics, among other functions.  

The Challenge

seoul_qfc

“5 billion people in the world don’t have access to safe surgery,” as reported by The Lancet in their Global Surgery Report 2030.

 

While patient outcomes in surgery have improved over the past decade - driven by better materials, implant designs, and surgical techniques - major obstacles remain to be addressed. Surgical patients still experience major discrepancies in success, including a 20-40% rate of failed back surgery syndrome (FBSS) according to the NCBI.  And with a rapidly aging world population - expected to grow from just over 900 million to nearly 1.5 billion between 2015 and 2030 according to Forbes– the stakes are higher than ever before. 

Inconsistencies in surgical training and high rates of burnout among orthopedic surgeons are some of the factors contributing to variations in patients outcomes.  At the same time, the high financial burden of associated with pre-, intra-, and post-surgery are being compounded by rising patient demand. The current model is unsustainable as analyzed in the Projection of Surgical Loads of Hip and Knee report[1].

Fortunately, tremendous opportunity awaits. Advancing technology can lead the industry to drastic improvements, a digital ecosystem where technologies enhance surgical performance, help educate surgeons, and guide patients through to full recovery. This digital ecosystem will amplify the surgeon’s ability through personalization, automation, and improved procedural efficiency throughout the continuum of care so that we reduce variability and help improve outcomes. 

The potential of digitally enabled technologies is significant, but we believe that existing solutions are not optimal especially in the area of robotics. Current robotics are large and complicated; they slow procedures down without improving accuracy; they require dedicated support, intensive training and cannot easily be shared between operating rooms or surgeons. 

That’s why Johnson & Johnson Medical Korea Ltd. in collaboration with Seoul Metropolitan Government (SMG) and Korea Health Industry Development Institute (KHIDI) are launching the Seoul Innovation QuickFire Challenge: Robotics & Digital Surgery. Up to two winning robotics and surgical solutions will receive up to KRW 150,000,000 (~$134,000)*, entrance to the Seoul Bio Hub, one year of mentorship and coaching, and access to the JLABS global entrepreneurial community.

 

[1]Gaiser S, Kapoun M. Projection of Surgical Loads of Hip and Knee. Heraeus Medical GmbH, Wehrheim, Germany; Hochschule Niederrhein, Krefeld, Germany

Areas of Interest

We encourage applications from innovators working on all aspects of robotics and digital health related to surgery.  Here’s what we mean: 

  • Patient Engaging Apps
  • Sensors/Wearables
  • Pre-surgery prep/prehab
  • Surgical Decision Support
  • Visualization
  • Robotics
  • Self-Enabled Rehab
  • Health Care or Patient Data Analytics

Why this challenge matters to us

We believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health.

Timeline

August 13th, 2018
Applications Open
October 5th, 2018
UTC
Application Deadline
November 14th, 2018
Winner Announcement at Seoul BioMedical International Conference

Apply Now

Submit your idea today!


Don’t miss the deadline

Awards

KRW 150,000,000 (~$134,000)*
  • Entrance to the Seoul Bio Hub
  • Mentorship/Coaching for 1 Year
  • Access to the JLABS global entrepreneurial community
  • *From the KRW 150 million grant, each winner will receive a KRW 70 million cash award and a KRW 5 million free space voucher which must be used toward the rent and utilities at the Seoul Bio Hub for a year

FAQs

Q: What if I’m having trouble accessing the portal/website?

A: Make sure your browser is up to date and accepting cookies. You can contact customer service at [email protected] / if you are having technical difficulties as well.

 

Q: For prizes involving residency at Seoul Bio Hub, what does that entail?

A: For this challenge involving residency at Seoul Bio Hub, that entails the entitlement to rent an office suite at Seoul Bio Hub, of which the size of suites starts from 24m2.  From the KRW 150 million grant, each winner will receive a KRW 70 million cash award and a KRW 5 million free space voucher which must be used toward the rent and utilities at the Seoul Bio Hub for a year.

 

Q: For prizes involving residency, are there any expenses not covered by Seoul Bio Hub?

A: Each winner will be responsible for its monthly rent and utilities. Each winner will receive a voucher to be used to cover one year of rent and utilities at Seoul Bio Hub. Please contact Seoul Bio Hub ([email protected]) for more information on rental cost. 

 

Q: Will JLABS or Seoul Bio Hub pay for my living costs, relocation or visas?

A: No, any additional fees and paperwork are up to the winner.

 

Q: Can I submit supporting documents (for example a video) as part of my application? 

A: You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

 

Q: Is it ok if some of the information I submit is confidential?

A: Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

 

Q: What happens with IP (Intellectual Property)?

A: As this is a no strings attached arrangement, JLABS does not acquire any IP.  Any IP creation and/or protection remains the sole responsibility of the inventors.

 

Q: Is a patent required to apply?

A: No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

 

Q: What kind of science / technology is appropriate for the Challenges? 

A: We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering

 

Q: Who is eligible to apply?

A: Each Challenge has its own terms & conditions that can be found prior to filling out the application.

 

Q: What are the specific criteria for application?

A:  Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Plans for utilizing Seoul Bio Hub
  • Idea submission outlines interest in the innovation ecosystem in Seoul

 

Q: Who can I contact if I have questions about the Challenges or the application process?

A: Please contact [email protected] with any questions.

 

Q: Where do I apply? And do I have to complete the application in one sitting?

A: You can setup an account at http:// jnjawards.fluidreview.com. You are able to save your work and log back in to finish at a later time if needed.

About Johnson & Johnson Innovation

 

jjic_innovation_logo_rgb_virtical_300dpi.png

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation – JLINX, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow

@JNJInnovation.

 

About Johnson & Johnson Innovation, JLABS

 

johnson-johnson-jlabs-7x4.jpgJohnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation, JLABS (JLABS), Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. New JLABS in NYC and Shanghai have been announced, and in February 2018, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe.  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

 

About the Seoul Metropolitan Government

 

Picture3.png

 

 

Seoul is a global city located at the center of Northeast Asia characterized by easy access to metropolitan cities around the world and convenient living conditions, particularly with nine (9) subway lines, 6,000 bus stops, and 22 international schools. 

The Seoul Metropolitan Area is an optimal location to foster technology-oriented venture firms as it houses more than 20,000 research institutes, 139 universities, and 133 general hospitals, concentrating top-caliber workforce and technology in a single location.

The Hongneung Biomedical Cluster, home to Seoul Bio Hub, which is slated to open in September 2017, houses national research institutes (KIST,etc.), research-oriented hospitals, and universities. The Seoul Metropolitan Government plans to offer facilities and equipment for the fast growth of technologically advanced startups and help businesses, researchers, and businessmen develop and commercialize innovative technologies via support in investment, administration, and information services.

 

About Seoul Bio Hub

 

Picture2.pngSeoul Bio Hub, located in northern Seoul and began operations in October 2017, is a life science innovation center sponsored by SMG and operated by KHIDI. The key function is to support early stage life science companies’ growth and commercialization by providing full-service wet laboratory and office spaces, shared equipment, networking events, training programs, and investor relation opportunities. As the only biotech startup platform located in Seoul, it leverages its geographical advantages to accelerate the startup ecosystem, by facilitating cooperative networks among research-driven hospitals, universities, national research institutes, and venture capitals within close vicinity. For more information, please visit http://www.seoulbiohub.kr.

 

About Korea Health Industry Development Institute (KHIDI)

 

KHIDI is a government-affiliated institution which performs professional and systematic support to develop domestic healthcare industry and enhance healthcare services. Since its establishment in 1999, KHIDI has led expansion of healthcare research and development investment and building competitiveness of Korea's healthcare industry, i.e., health services, pharmaceuticals, medical devices, food and beauty-cosmetic. KHIDI is designated as an operating body of Seoul Bio Hub, and plans to utilize its infrastructure and network to facilitate cooperation with relevant stakeholders. For more information, please visit http://www.khidi.or.kr/eps.

 

About the Johnson & Johnson Medical Devices Companies

 

The Johnson & Johnson Medical Devices Companies’ purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs and research and development capabilities in surgical technology, orthopaedics, cardiovascular and specialty solutions with an offering directed at delivering clinical and economic value to health care systems worldwide.

            

PExA

PExA AB is a Swedish start-up company that has developed a breakthrough technology enabling
collection of biomaterial from the small airways with potential in discovery of respiratory biomarkers

Focus area
Diagnostics

JLABS @ M2D2 QuickFire Challenge

JLABS @ M2D2 QuickFire Challenge
Challenge ended

Residency at JLABS @ M2D2

Diabetes
Neurovascular
Orthopedics
Surgery
Vision care
Image paragraph

Third Pole is producing next generation cardio-pulmonary therapies that expand patient access. Our first product creates inhaled nitric oxide on-demand, on-site from air. Powered by this innovative portable technology licensed from Massachusetts General Hospital we eliminate the need for cumbersome compressed gas cylinders and enable the worldwide use of inhaled NO in settings outside of acute care.

The Challenge

We are looking for game-changing early-stage medical device innovations and therapeutic platforms across Johnson & Johnson’s strategic areas of interest:

  • Cardiovascular
  • Diabetes
  • Neurovascular
  • Orthopedics
  • Surgery
  • Vision Care

Entrants must be committed to conducting their project at the M2D2 space in Lowell, MA.

Rewards and benefits

Space at JLABS @ M2D2

Why this challenge matters to us

At Johnson & Johnson Innovation, we believe the next great idea can come from anywhere – and that it’s just as likely to come from outside of our walls as from inside our research labs. That’s why Johnson & Johnson Innovation is excited to announce JLABS @ M2D2, our accelerator initiative in partnership with the northeast region’s premier medtech incubator, University of Massachusetts Medical Device Development Center (M2D2) in Lowell, Massachusetts. JLABS @ M2D2 is our seventh JLABS facility and the first specifically focused on the early-stage medical device ecosystem.

Timeline

PST
Deadline to apply
PST
Announcement of winners

Check out the blog post on the J&J website!

Advancing the Safe Use of Healthcare Products QuickFire Challenge

Advancing the Safe Use of Healthcare Products QuickFire Challenge
Advancing the Safe Use of Healthcare Products QuickFire Challenge
Challenge ended

Up to $200,000 USD*

Consumer Health
Digital Health
Surgery

Winner

Image paragraph

CertaDoseTM offers a unique measuring system that helps eliminate dosing errors in kids by using any of the industry standard methods of estimating a patient’s weight, including length and age, and automatically converts that weight to the appropriate dosage on our color-coded syringe.  CertaDoseTM is an FDA-cleared syringe clinically proven to reduce critical dosing errors to zero. Each syringe is labeled with easy to recognize color zones that match the Broselow® color system to help clinicians verify the correct dose during critical, time-sensitive situations.

The Challenge

Image paragraph

At the Johnson & Johnson Office of the Chief Medical Officer (OCMO) we strive to enable healthcare practitioners, physicians, surgeons, patients and consumers to use our products safely by providing the most complete information and the best education and training we can.

To that end, Johnson & Johnson Innovation and the OCMO are looking to reward up to $200,000 in multiple grants, and one year of JLABS space, to the individuals or teams who submit the best ideas on how to educate, inform and provide clarity around healthcare product safety.

Rewards and benefits

Up to $200,000 USD*
  • *in grants for multiple winners
  • Entrance to an available JLABS
  • Mentoring & Coaching

QuickFire Challenge innovation focus areas

Empowering patients and consumers to make more informed healthcare decisions by providing better information and education about the safety of healthcare products (pharmaceuticals, medical devices and consumer products).

This challenge focus area seeks ways to maximize consumer and patient education and understanding of healthcare products and their safety and efficacy, including medical devices, pharmaceuticals and consumer products.

The objective is to empower patients, consumers and healthcare providers to make more informed decisions and obtain maximum benefit from product use through greater understanding of safety data and by ensuring more effective communication and enhancing education.

Image paragraph

Improving training and development for surgeons by identifying new models that simulate the operating room environment.

This focus area seeks new and robust models and methods to evaluate medical devices used by surgeons in a simulated environment representative of operating room procedures, with the goal of helping the surgeon understand how to safely and effectively use a medical device and understand variability in device and performance/outcome.

Entries should focus on soft tissue models that anatomically represent organ-specific anatomic features and biological properties, such as tissue injury, bleeding and clotting responses.

Image paragraph

Empowering patients and consumers to more safely administer and handle healthcare products.

The third focus area seeks ways to address the challenge of prescription medication errors. Entries should identify patient- and consumer-focused devices, solutions or platforms that will prevent errors and solutions to promote safe storage and administration or extend the shelf life of prescription, over-the-counter or cosmetic products.

Image paragraph

Timeline

CST
Applications Open
CST
Submission Deadline
CST
Winner Announced

Why this challenge matters to us

True benefit from healthcare products requires an unrelenting focus on patient- and consumer-centered safety, a principle that is at the heart of Johnson & Johnson’s Credo and is embodied in the mission of the Office of the Chief Medical Officer (OCMO).  Working to ensure that J&J is developing and making available the safest products possible is what the nearly 1000 employees of OCMO work towards each day.  Always looking for better ways to address safety on behalf of patients and consumers, we are embarking on a Quickfire Challenge to identify new and innovative ideas to increase the safe use of our products.

Application process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential to impact healthcare outcomes / move the needle on medical safety
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Clarity of plan: Milestones & defined go/no go decisions

Deadline to apply is May 24, 2017
Winner(s) will be announced in November

About Johnson & Johnson Office of the Chief Medical Officer

Established in 2013, the Johnson & Johnson Office of the Chief Medical Officer (OCMO) is accountable for bringing scientific excellence, bioethics- and values-driven decision-making, as well as a commitment to transparency and medical safety assessments that are independent of commercial interests, to the many efforts that keep patients and consumers at the heart of everything we do. The OCMO has oversight across Johnson & Johnson for medical safety, epidemiology, R&D operations and creating and maintaining global bioethical policies.

 

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation – JLINX, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

 

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

Image paragraph
Image paragraph

You can find our press release here.

Artificial Intelligence for Drug Discovery QuickFire Challenge

JLABS - Artificial Intelligence for Drug Discovery QuickFire Challenge
Artificial Intelligence for Drug Discovery QuickFire Challenge
Challenge ended

Up to $100,000 USD*

Immunology

Winners

 

A2A

A2A Pharmaceuticals: At A2A Pharmaceuticals, our mission is to leverage proprietary computational systems including A.I., to accelerate development of novel drug alternatives for life threatening diseases like cancer, bacterial infections and muscular dystrophy.  

 

Envisagenics

Envisagenics: Cloud-based drug-target discovery platform (SpliceCore) using AI to predict disease-causing aberrant splicing through the analysis of massive amounts of RNA-seq data. 

 

Traceryo

Tracery Ophthalmics: Tracery is a clinical stage ocular imaging and health tech company focused on Age Relate Macular Degeneration and blinding eye disease.  

The Challenge

Image paragraph

At Johnson & Johnson Innovation and Janssen Research & Development our goal is to improve the health and wellness of people around the world. Artificial intelligence (AI) poses unlimited opportunity for us to make a transformative impact on patients. Whether it be through new drug combinations, improved medical diagnostics, better accuracy in personalized medicine, or many other benefits - AI could save scientists valuable research time and bring new treatments to patients more quickly. To that end, Johnson & Johnson Innovation is looking to award up to $100,000 in grants, one year of JLABS residency & mentorship to the individuals or teams who submit the best ideas, technologies, or solutions that are using artificial intelligence to advance healthcare.

Rewards and benefits

$100,000*
  • *Up to $100,000 USD in grants for multiple winners
  • Residency at an available JLABS location
  • Mentoring & coaching from J&J experts

QuickFire Challenge innovation focus areas

We are looking for entrepreneurs & innovators with the best ideas, technologies, or solutions across all stages (ideation, pre-clinical, clinical, post-approval) that are using artificial intelligence to advance drug discovery & development in any of these areas:

  • Oncology & Immuno-oncology
  • Immunology
  • Cardiovascular & Metabolism
  • Infectious Diseases & Vaccines
  • Neuroscience
  • Pulmonary Hypertension
  • Rare Diseases
  • Pre-clinical safety studies
  • Systems pharmacology
  • Clinical trials
  • Precision Medicine
  • Chemo-informatics
  • In silico compound & safety profiling
  • Real world evidence

Timeline

EST
Applications Open
EST
Submission Deadline
EST
Judging Commences
EST
Finalists Pitch at JLABS @ Toronto and Winners are Announced 

Application process

A panel of reviewers and judges will evaluate submissions based  on their ability to meet the following criteria:

  • Scientific/Technical Excellence
  • Novelty
  • Feasibility/Practicality
  • Perceived commercialization potential
  • Clarity on milestones and deliverables
  • Quality of Team and Resources
  • Plan for use of funds


Deadline to apply is October 27th, 2017
Winner(s) will be announced in December

About the Janssen Pharmaceutical Companies

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at Twitter.com/JanssenGlobal.

 

About Johnson & Johnson Innovation

Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JLINX, Johnson & Johnson Innovation – JJDC and our Business Development teams to create customized deals and novel 4 collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.


About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

Image paragraph
Image paragraph

Singapore QuickFire Challenge - Metabolic Disease Innovation

Singapore Quickfire Challenge
Singapore QuickFire Challenge - Metabolic Disease Innovation
Challenge ended

Up to SGD100,000

Consumer Health
Diagnostics
Digital Health
Therapeutics

Winners

Image paragraph

Nanyang Technological University (LambdaGen) envisions development of next generation personalized therapeutics using its proprietary non-viral technological advance based on λ-integrase system that allows insertion of large fragments of DNA in a discrete number of non-random insertion sites which can be used to treat a wide range of diseases where a functional copy of a large disease-causing/therapeutic gene is required.

Image paragraph

PreventAGE Health Care, led by an experienced team, is driven by the grand ambition to fundamentally improve the lives of patients with diabetes by providing biomarker-based prognostic, actionable information on their personal risk for developing specific complications (nephropathy, retinopathy, cardiovascular diseases) far in advance of any symptoms so as to preserve health and to reduce costs.

Image paragraph

Medopad is a CE-marked patient monitoring software solution that brings together modular care monitoring tools, patient vital data tracking, and real time AI analytics to provide an easy-to-use yet holistic digital health solution.

The Challenge

Image paragraph

Johnson & Johnson Innovation, JLABS (JLABS) in collaboration with Exploit Technologies Pte Ltd (ETPL) and Singapore-MIT Alliance for Research and Technology (SMART), have launched the Singapore QuickFire Challenge - Metabolic Disease Innovation to attract game-changing, early stage innovations that address this critical health concern.

Metabolic diseases such as diabetes and obesity are posing a threat to Asia Pacific like never before. Globally, over 422 million people are living with diabetes today, and about 60% of them are in Asia. The disease burden in the region continues to evolve in epidemic proportions.

Rewards and benefits

Up to SGD100,000
  • Up to SGD100,000 in potential project money for winners*
  • Access to ETPL laboratory space
  • One year of mentoring and support for winners from the Johnson & Johnson Innovation, ETPL and SMART staff
  • * At least one core team member of the applicant must reside in Singapore for no less than 50 percent of the term of the project.

Areas of interest

This global competition will award the person or team(s) who submits the best idea, technology, or solution focused on metabolic disease in the following areas:

  • Therapeutics
  • Health technologies
  • Consumer healthcare
  • Medical devices
  • Diagnostics

Why this challenge matters to us

This Challenge aims to identify and support entrepreneur, academic, and biotech researchers with innovative ideas that have the potential of making a major difference in the lives of the millions of people in Asia Pacific and around the world who suffer from metabolic diseases such as diabetes and obesity.

Frequently Asked Questions

What is being awarded and to how many innovators/companies?

Each of up to three winners will be awarded SGD100,000 for research in Singapore, access to ETPL laboratory space and one year of mentorship and coaching by Johnson & Johnson Innovation, ETPL and Singapore-MIT Alliance for Research and Technology (SMART) staff.

Where do I apply?

You can apply through https://jnjawards.fluidreview.com/

Who is eligible to apply?

We encourage applications from everyone interested in the QuickFire Challenge however, per the terms and conditions not all applicants may be eligible to win the QuickFire Challenge.

What sectors are you looking for?

Solutions addressing metabolic disease in the Asia Pacific region in the following areas:
• Therapeutics
• Medical devices
• Consumer health
• Diagnostics
• Health technologies

What are the specific criteria for application?

All applicants must outline how the award will help them reach a critical milestone with the timeframe of a single year and provide a full “time-to-market” plan for their solution. Solutions need to meet the following criteria:
• Address a metabolic disease in the Asia Pacific region
• Integrate a novel approach within the therapeutic, device, diagnostic, consumer health and/or health technologies areas
• Address part or all of the spectrum of prevention, interception and cure

Do applicants have to reside in Singapore in order to apply?

No, this is a global challenge. However, if selected as a winner or finalist, at least one core team member of the applicant company must reside in Singapore for no less than 50 percent of the term of the project.

Can I submit supporting documents (for example a video) as part of my application?

You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

Is it ok if some of the information I submit is confidential?

Do not submit confidential information. Only non-confidential information should be submitted.

*For further information on eligibility for this QuickFire Challenge, please refer to the Terms & Conditions presented in your application form.

Application process

The submitted metabolic disease solutions will be evaluated based on their ability to meet the following criteria:

  • Address a metabolic disease in the Asia Pacific region
  • Integrate a novel approach within the therapeutic, device, diagnostic, consumer health and/or health technologies areas
  • Address part or all of the spectrum of prevention, interception and cure
  • Idea submission is innovative and creative
  • Idea submission is scalable
  • Idea submission outlines how the award would help them reach a critical milestone within the timeframe of a single year and provides a full commercialization plan.

You have to sign up for an account to get started, and you will receive an email to activate your account. You will be guided through the application process which will include signing our general Terms and Conditions Agreement, filling out your application form and uploading your non-confidential project plan.

Timeline

SGT
Enter
SGT
Submission deadline
SGT
Judging process begins
SGT
Finalist mentoring sessions begin
SGT
Finalists live presentations to Judges
SGT
Winner Announcement

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation – JLINX, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

 

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

Image paragraph
Image paragraph

DRUID Ltd

Developing a multi-use diagnostic nappy/diaper to detect the presence of sugar within a baby’s/toddler’s urine and associated ketones within the urine.

Focus area
Diabetes
Diagnostics

Advancing Joint Replacement Surgery QuickFire Challenge

21_04_16_Next_Gen
Advancing Joint Replacement Surgery QuickFire Challenge
34 days remaining

Up to $50,000 grant funding

Medical Devices
Orthopedics
Surgery

Overview

Every year, more than 27 million orthopaedic procedures are performed across the globe.[1]

As more patients require orthopaedic care globally, the R&D organization of Depuy Synthes, the Orthopaedic Company of Johnson & Johnson, is helping to shape the standard of modern day care, including forging new capabilities in surgical robotics. To continue to help lead the industry’s digital transformation, Depuy Synthes is committed to ongoing innovation across the care continuum to keep patients, surgeons, and the industry moving forward.

While great strides have been made in robotic surgery[2], the future of intra-operative surgical solutions for patients undergoing orthopaedic joint replacement surgery has the potential to continue to reduce cost, increase efficiency and improve usability, and simplify procedures.

To that end, Johnson & Johnson Innovation, together with the R&D organization of DePuy Synthes, announces the Advancing Joint Replacement Surgery QuickFire Challenge. Innovators are invited to submit concepts, prototypes and developed technologies that could potentially address current technology limitations in orthopaedic joint replacement surgery, such as:

  • Cost: High cost of capital equipment and per procedure disposable cost
  • Usability: Poor user experience including loss of tactile feedback, time inefficiency, and constraints on OR layout
     
  • Complexity: Injury and pain associated with pin sites used for bone markers, requirement to maintain line of sight with optical tracking arrays, inefficient and inaccurate bone registration

The innovator(s) with the best idea, technology, or solution aimed at advancing surgical solutions for orthopaedic joint replacement surgery will receive grant funding up to $50,000, access to the global Johnson & Johnson Innovation - JLABS network and mentorship from experts at the Johnson & Johnson Family of Companies.

 

[1] Global Orthopedic Surgery Market Report, 2017 to 2022. Research and Markets. Accessed April 2021.

[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356187/

Awards

Up to $50,000 grant funding
  • Access to the global Johnson & Johnson Innovation – JLABS ecosystem
  • Mentoring from experts within the Johnson & Johnson Family of Companies

Areas of Interest

Innovators are invited to submit concepts, prototypes and developed technologies that could potentially address current technology limitations in orthopaedic joint replacement surgery including reducing cost, increasing efficiency and improving usability, and simplifying procedures.

Specific areas of focus for the challenge include advanced methods of bone tracking and registration to enable either smart surgical tools or a next generation robotic solutions, eliminating the need for line of sight tracking using pin-based optical arrays.

We are specifically interested in applications that meet the following criteria:

  • Fast bone registration (<30s, <1mm, 1deg accuracy)
  • Markerless or minimally invasive tracking solutions (<1mm, 1deg accuracy)
  • Accommodate the majority of OR layouts, workflows, surgical staff (PA, scrub tech etc.) positions
  • Low-cost solutions with per case disposable cost of <$50USD
  • User friendly with few surgical steps and a small footprint
  • Image-free (standard Xray only)

Application Process

Potential solutions will be evaluated by a panel of reviewers and judges on the solutions’ ability to meet the following criteria:

  • Technical Alignment
    • Accuracy
    • Minimal or non-invasive attachment of markers, if any, to bone
    • Size and footprint of equipment
    • Per case disposable cost <$50USF
    • Potential scalability of manufacturing to produce multi-millions per year
  • Uniqueness of Idea/Solution
  • Commercialization potential
  • Time to market 

Why this challenge matters to us

At Johnson & Johnson Innovation, we believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that aim to provide solutions to patients from across the world. Working together, we can spark the next great idea that can potentially change the trajectory of health.

Apply Now

Submit your idea today!


Don’t miss the deadline

FAQs

What if I’m having trouble accessing the portal/website?

Make sure your browser is up to date and accepting cookies. You can contact customer service at [email protected] if you are having technical difficulties as well.

Can I submit supporting documents (for example a video) as part of my application?

You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

Is it ok if some of the information I submit is confidential?

Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

What happens with IP (Intellectual Property)?

As this is a no strings attached arrangement, JLABS does not acquire any IP.  Any IP creation and/or protection remains the sole responsibility of the inventors.

Is a patent required to apply?

No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

What kind of science / technology is appropriate for the Challenges?

We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering

Who is eligible to apply?

Each Challenge has its own terms & conditions that can be found prior to filling out the application.

What are the specific criteria for application?

Potential solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact to transform human health
  • Uniqueness of the idea
  • Feasibility of the idea
  • Thoroughness of approach
  • Identification of key resources and a plan to further the idea

Who can I contact if I have questions about the Challenge or the application process?

Please contact [email protected] with any questions.

Where do I apply? And do I have to complete the application in one sitting?

Go to https://jnjquickfire.secure-platform.com to learn more. From there you will be directed to set up an account.

Timeline

April 27, 2021
Applications Open
June 18, 2021
Submission deadline
Fall 2021
Award Announcement

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation - JLABS; JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive, all with no strings attached. A Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation, please visit: www.jnjinnovation.com.

 

About Johnson & Johnson Innovation - JLABS

Johnson & Johnson Innovation – JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS, we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS also produces campaigns to seek out the best science called QuickFire Challenges. For more information, visit www.jlabs.jnjinnovation.com or follow @JLABS.

 

DePuy Synthes

DePuy Synthes, the Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement for the millions of patients we serve. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sport medicine, in addition to the VELYSTM Digital Surgery portfolio, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide.